GALT: Galectin Therapeutics Inc. Company Value to Net Income

Symbol and logo of brand Galectin Therapeutics Inc. (GALT)

Galectin Therapeutics (GALT) focuses on developing advanced galectin inhibitors to combat oncology and fibrosis. This price chart confirms investments in these R&D efforts, which currently stand at -7.50. The biotech's success depends on the outcomes of Phase II clinical trials for cirrhosis treatments amid stable capital. Additionally, Galectin Therapeutics (GALT) targets the treatment of advanced disease stages, which will ensure long-term patent revenue.

GALT - Galectin Therapeutics Inc. P/E Multiple over the range 07/04/2022 - 11/13/2026

Comprehensive metric breakdowns and analytics for Galectin Therapeutics, Inc. (GALT)

- price and consensus price forecast:
Stock Price Galectin|GALT - Consensus Target
- market capitalization information:
Market Value Galectin Therapeutics Inc.|GALT - Total Company Value
- balance sheet net asset value indicators:
Net Assets per Single Share Galectin Therapeutics|GALT - Book Capitalization|Market Capitalization to Book Value galectintherapeutics.com|GALT - Cumulative Company Assets
- company liabilities and liquidity data:
Debt to Equity Galectin Therapeutics|GALT - Long-Term Debt to Capital|Current Liabilities to Capital Galectin|GALT - Company Debts|Debt to Net Assets Ratio Galectin Therapeutics Inc.|GALT - Company Long-Term Debts|Short-Term Indebtedness Galectin Therapeutics|Quick Ratio galectintherapeutics.com
- earnings and market ratios statistics:
GALT - Company Net Income|Expected Profit Galectin Therapeutics|GALT - P/E Multiple|Projected Price to Earnings Ratio Galectin|GALT - PEG Multiple|Enterprise Value to EBITDA Ratio Galectin Therapeutics Inc.|GALT - Operating profit before deduction of amortization|Earnings per share for the last four quarters Galectin Therapeutics|GALT - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months galectintherapeutics.com|GALT - Earnings per share growth in current year|Projected earnings per share growth rate for next year Galectin Therapeutics
- company sales and revenue statistics:
GALT - Company Sales|Company Future Revenue Galectin|GALT - Market Cap to Revenue|Price to Expected Revenue Ratio Galectin Therapeutics Inc.
Comprehensive company analysis:galectintherapeutics.com - GALT
Brand item of Galectin Therapeutics Inc.

P/E measures the density of invested capital through the ratio of a stock's market value to net income, reflecting the balance of supply and demand in the order book. The P/E valuation for Galectin Therapeutics (GALT) is specific, as the academic R&D model and the costs of elite biochemists temporarily suppress current earnings. The dynamics of this indicator demonstrate the market's attitude toward long-term grants and the potential of fibrosis therapy. Low values confirm a conservative valuation but highlight a deficit of institutional interest.

Key competitors

P/E Multiple arrowheadpharma.com|Price to Earnings Ratio MIRM (Mirum)|DVAX (Dynavax Technologies) - Company Value to Net Income|Price to Earnings Ratio Arbutus ABUS|Inventiva Corp - Price to Earnings Ratio|Gyre Therapeutics, Inc. - P/E Multiple|Business Payback Period assemblybio.com ASMB|GNFT (genfit.com) - Price to Earnings Ratio|DRRX (DURECT) - Price to Earnings Ratio|ALGS (Aligos Therapeutics Inc.) - P/E Multiple|Market Cap to Earnings BioVie Pharma BIVI|Price to Earnings Ratio Galmed Pharmaceuticals (GLMD)|NDRA (endrainc.com) - Company Value to Net Income|P/E Multiple HEPA (Hepion Pharmaceuticals, Inc.)